The triple combination of RA, tunicamycin, and ATO decreases the colony-forming capacity of primary leukemic blasts bearing the FLT3-ITD mutation, leading to AML cell death without affecting healthy HSPCs [18]. Here, FLT3 is linked to acute myeloid leukemia.